BVF as of Dec. 31, 2024
Portfolio Holdings for BVF
BVF holds 53 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 36.2 | $1.1B | 20M | 54.15 | |
| Kymera Therapeutics (KYMR) | 7.0 | $208M | 5.2M | 40.23 | |
| Revolution Medicines (RVMD) | 6.2 | $183M | 4.2M | 43.74 | |
| Axsome Therapeutics (AXSM) | 4.0 | $117M | 1.4M | 84.61 | |
| Mirum Pharmaceuticals (MIRM) | 3.9 | $116M | 2.8M | 41.35 | |
| Xoma Royalty Corporation Com New (XOMA) | 3.2 | $96M | 3.6M | 26.28 | |
| Protagonist Therapeutics (PTGX) | 2.5 | $73M | 1.9M | 38.60 | |
| Gh Research Ordinary Shares (GHRS) | 2.5 | $73M | 10M | 7.00 | |
| Cullinan Oncology (CGEM) | 2.4 | $70M | 5.8M | 12.18 | |
| Zymeworks Del (ZYME) | 2.1 | $63M | 4.3M | 14.64 | |
| Septerna (SEPN) | 1.9 | $56M | 2.5M | 22.90 | |
| Tyra Biosciences (TYRA) | 1.9 | $55M | 3.9M | 13.90 | |
| Ac Immune Sa SHS (ACIU) | 1.8 | $53M | 20M | 2.70 | |
| Xencor (XNCR) | 1.8 | $53M | 2.3M | 22.98 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 1.6 | $48M | 1.8M | 27.12 | |
| Celcuity (CELC) | 1.5 | $45M | 3.5M | 13.09 | |
| Galapagos Nv Spon Adr (GLPG) | 1.5 | $43M | 1.6M | 27.50 | |
| Verve Therapeutics (VERV) | 1.3 | $39M | 6.9M | 5.64 | |
| Annexon (ANNX) | 1.2 | $36M | 7.0M | 5.13 | |
| Agios Pharmaceuticals (AGIO) | 1.2 | $35M | 1.1M | 32.86 | |
| 89bio (ETNB) | 1.1 | $34M | 4.3M | 7.82 | |
| Olema Pharmaceuticals (OLMA) | 1.1 | $33M | 5.7M | 5.83 | |
| Cidara Therapeutics Com New (CDTX) | 1.0 | $29M | 1.1M | 26.88 | |
| Eledon Pharmaceuticals (ELDN) | 0.9 | $26M | 6.3M | 4.12 | |
| Foghorn Therapeutics (FHTX) | 0.8 | $25M | 5.3M | 4.72 | |
| Third Harmonic Bio (THRD) | 0.8 | $24M | 2.4M | 10.29 | |
| Kura Oncology (KURA) | 0.8 | $22M | 2.6M | 8.71 | |
| Allakos | 0.7 | $20M | 17M | 1.21 | |
| Monte Rosa Therapeutics (GLUE) | 0.7 | $19M | 2.8M | 6.94 | |
| Iteos Therapeutics | 0.6 | $18M | 2.3M | 7.68 | |
| Essa Pharma Com New (EPIX) | 0.5 | $16M | 8.7M | 1.79 | |
| 4d Molecular Therapeutics In (FDMT) | 0.5 | $15M | 2.7M | 5.57 | |
| Rapt Therapeutics | 0.5 | $15M | 9.2M | 1.58 | |
| Engene Holdings (ENGN) | 0.5 | $14M | 2.1M | 6.65 | |
| Repare Therapeutics Ord (RPTX) | 0.5 | $14M | 10M | 1.31 | |
| Forte Biosciences Com New (FBRX) | 0.5 | $14M | 594k | 22.71 | |
| Verastem Com New (VSTM) | 0.4 | $11M | 2.1M | 5.17 | |
| Tscan Therapeutics (TCRX) | 0.3 | $9.1M | 3.0M | 3.04 | |
| Immunic (IMUX) | 0.3 | $8.9M | 8.9M | 1.00 | |
| Palvella Therapeutics Inc Ne (PVLA) | 0.3 | $8.4M | 697k | 12.00 | |
| Avalo Therapeutics Com New (AVTX) | 0.3 | $7.7M | 1.0M | 7.43 | |
| Ikena Oncology (IKNA) | 0.2 | $6.6M | 4.0M | 1.64 | |
| Molecular Partners Ads (MOLN) | 0.2 | $6.5M | 1.4M | 4.77 | |
| Cytomx Therapeutics (CTMX) | 0.2 | $5.4M | 5.2M | 1.03 | |
| Ovid Therapeutics (OVID) | 0.1 | $3.6M | 3.9M | 0.93 | |
| Sab Biotherapeutics Com New (SABS) | 0.1 | $3.5M | 918k | 3.82 | |
| Vigil Neuroscience (VIGL) | 0.1 | $3.1M | 1.8M | 1.70 | |
| Glycomimetics | 0.1 | $2.4M | 9.5M | 0.25 | |
| Tenax Therapeutics Com New (TENX) | 0.1 | $2.1M | 340k | 6.19 | |
| Elevation Oncology (ELEV) | 0.1 | $1.7M | 3.0M | 0.56 | |
| Inventiva Sa Ads (IVA) | 0.0 | $1.5M | 686k | 2.15 | |
| Engene Holdings *w Exp 10/31/202 (ENGNW) | 0.0 | $804k | 945k | 0.85 | |
| Nls Pharmaceutics Com New (NLSP) | 0.0 | $303k | 144k | 2.11 |
